Replies to post #106304 on Biotech Values

[mcbio]

Re: Roche/Danoprevir

Roche Reports 3Q10 Sales, Reiterates 2010 Guidance

[Roche reports earnings only for half-year periods, so the 3Q10 results include sales but not earnings. The long version of Roche’s PR is at www.roche.com/inv-update-2010-10-14-e.pdf .]

I'm anxious to listen to this conference call for any specific Danoprevir guidance (http://www.roche.com/investors/ir_agenda/q3-2010.htm ). I plan to do so tonight, but let me know in the interim if you've had a chance and if there are any relevant highlights. FWIW, the long version of the PR has one brief sentence on page 6 of 26 relevant to Danoprevir that states the following:

"In addition, with the acquisition from InterMune in early October of the full rights to danoprevir (RG7227, ITM-191), a promising second-generation protease inhibitor, Roche has further strengthened its leading position in the development of innovative treatments for hepatitis C."